mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt - Test2 - elhamkhani - TriplyDB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

http://www.wikidata.org/entity/Q29547767

about

PI3K/AKT/mTOR Pathway in Angiogenesis Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus Analysis of the genome to personalize therapy for melanoma Mammalian target of rapamycin: a central node of complex signaling cascades Updates of mTOR inhibitors Cixutumumab mTOR inhibitors in advanced renal cell carcinoma Pushing the envelope in the mTOR pathway: the second generation of inhibitors The mTOR signalling pathway in human cancer Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy Akt and autophagy cooperate to promote survival of drug-resistant glioma The PI3K pathway as drug target in human cancer Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy mTOR: from growth signal integration to cancer, diabetes and ageing Rapamycin and mTOR kinase inhibitors NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas Targeting the mTOR signaling network for cancer therapy Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors Targeting mTOR in Pancreatic Ductal Adenocarcinoma Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Fortifying the Treatment of Prostate Cancer with Physical Activity Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics The PI3K/Akt Pathway in Tumors of Endocrine Tissues PI3K/Akt/mTOR inhibitors in breast cancer MEK and PI3K inhibition in solid tumors: rationale and evidence to date Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers PI3K and AKT: Unfaithful Partners in Cancer Toward rapamycin analog (rapalog)-based precision cancer therapy

P2860

Q21129332-574FFA63-B7EA-4975-A21E-50337F56B76D Q21133610-C5288E65-FFF4-40ED-BFFF-68C490737237 Q21145847-678E12E4-6EFC-4E77-B7F5-848AFA0FBB15 Q21183974-71FC4EEA-F932-4C0B-831A-BBDF30421398 Q21245750-762D66A0-65BE-4A2E-BFAC-EB138D918ED1 Q21261315-C408C5D6-1951-457A-BCEE-5D089CEC0E10 Q21328702-9A06A2C3-B418-40A3-AFE0-D96D4237274C Q24295146-FCDABA32-AD6D-4E83-BCB8-0B6F682162DE Q24300205-B51806A8-C0F0-41F7-B74C-352A5F6EE5C6 Q24311448-97C3B6E5-B044-440F-A46D-3D19B32C9C23 Q24322676-D9FB2AB4-3852-4AFC-9F77-C5A3229901EF Q24338724-9CCB65BE-F7BC-470E-B2E5-83DEFB4494EA Q24600932-F09E2727-66E9-47E3-9BE6-A1B8768FB41A Q24601008-01558475-164A-4DCF-87AB-4C7BDAEE9334 Q24601702-63ED4C0A-AC41-4A11-BE20-A71C8998B46A Q24607170-47D268BE-CEFE-4CC8-9E84-5BFC315F5B7B Q24609058-339A2BF2-81B8-47FF-B0CB-8FFDF572765B Q24612127-92F20F42-BD08-419D-84AA-D7F2123AEAE3 Q24622222-904AF2E8-28BB-4456-841F-FA2BBA73F604 Q24627306-1529B9D9-36BF-4E15-ACA0-4C5BE7E2D28B Q24628724-64DC5F18-DF7B-4184-B74D-3E0DB6FBEA7E Q24629677-18A24E51-29D7-41B8-9446-2B5EB5895EA9 Q24632283-09F52E97-49E1-4C60-AA57-BC9176F87493 Q24632296-C0B3E458-7E5B-478A-A915-643CC148BC98 Q24633662-6FF85BFB-009B-4313-B252-99B0DFACC171 Q24644623-5CDE13C1-1125-4FCF-A860-2250583FD675 Q24646237-EF65BAD6-0698-4B07-BDE6-B9E9B168D857 Q24658334-CF5BC8AB-4D18-43B5-9ECB-AE393BDCF776 Q24670558-D47BEF5D-46DF-456C-86BE-F039B113ADA8 Q26740374-3B1987AA-81BF-4A9D-886B-0A60CE4CAA1E Q26747291-6EF1DF9B-DDCE-454C-9D54-19DB61315FE0 Q26751344-AECF7449-74FB-4CCE-B77D-8396759F7DBE Q26765503-F005BCE7-8B0E-4A61-8DCA-8584B40EE191 Q26766292-3B487CE2-12F1-4893-A825-E02EC7C910E0 Q26770404-F1B8B798-849E-41D5-9C03-DC4AB9E905C1 Q26771394-EEA4A3A4-BB68-4FC5-B157-9D83403CD852 Q26775573-1A72BF4C-4C1A-45D1-84C6-BD5FEA896F45 Q26781362-CC1EF1B2-5FA2-4BAB-AB6C-F3D43AECC24F Q26781367-9923633E-CFF8-4EAC-9185-62FF3909EF9C Q26795606-4DC4D80B-107C-451F-BF3F-87AE9A320E8C

P2860

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

http://www.wikidata.org/entity/Q29547767

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@ast

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@en

type

label

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@ast

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@en

prefLabel

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@ast

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@en

P1433

Q29547767-B2D10FDB-6EAA-4DC7-B4DF-37A4F5838216

P1476

Q29547767-40311105-AE3D-4ED9-A8F1-8703B9CC43BF

P2093

Q29547767-418BE0D0-DF38-492D-9C75-181A5F91F52E

Q29547767-6965E42C-6BDF-4327-8ECD-F3702F407C4F

Q29547767-755D1A92-7834-47E3-8061-70666E7BA9C5

Q29547767-7BB3A33A-09BA-4F47-9492-6C56A1F82D01

Q29547767-864954F1-634C-4402-831D-521314117939

Q29547767-A8E197AB-2CD4-4C04-992D-B3A092459979

Q29547767-BC096C3D-D03F-4117-B7E5-FE5581DEA65E

Q29547767-C60684D8-D615-4C26-BA53-6C9C3894A973

Q29547767-DE361423-8F5A-409C-AADA-2EA3BC019D47

Q29547767-E6D80962-EF4F-49BA-9F4D-0FB651E11B5E

P2860

Q29547767-1301310A-02AD-4BC7-9349-460C8CD8E946

Q29547767-153DA176-E719-4F7E-AA7C-6D364724C82E

Q29547767-19A123E7-BF30-4CD8-B085-56D1EADFCBF9

Q29547767-19FAB5BF-9670-429C-A74F-C8DD1E3973CF

Q29547767-1D789C4E-6C0D-41D5-87A9-C7CC2CB628C4

Q29547767-22CEABF6-FCD9-4C39-965A-C0314245D876

Q29547767-35D8419F-916F-4B10-B0E7-84A8C5F43116

Q29547767-40322DFA-38E7-4A00-B265-35B55C82BA2A

Q29547767-4A7FE73F-A4E7-4811-AB7E-C991408F91F5

Q29547767-506F770D-7613-4241-A6CB-C591F4B97F32

P304

Q29547767-B17565C6-6891-4B83-9F1E-A6C5AECA7B85

P31

Q29547767-4AB035E3-B50E-4676-9A2C-36DD35C189AD

P3181

Q29547767-371F3F26-E72A-43B8-87BF-2F7C875DA9FC

P356

Q29547767-7F6EE0EB-B14F-4064-A88A-AA71BEB0D26F

P407

Q29547767-93C86641-5A48-4E4A-A2C7-B071EE21E17F

P433

Q29547767-1CEFF0B6-25C0-4D61-B398-103AE0BEAB10

P478

Q29547767-55F58AB6-3C5B-4AB8-A9D9-549007090A6A

P50

Q29547767-7F00246F-98DD-48B1-8343-72F353C7E773

P577

Q29547767-09D4E1C0-6868-49BE-9B14-DB20D0CE4F4A

P698

Q29547767-BF57544F-E95D-4F72-9F89-3CDB85407731

P932

Q29547767-AC9BDD1D-7D1C-4000-B36E-1F6FC91AE861

P3181

P356

0008-5472.CAN-05-2925

P1433

Cancer Research

P1476

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

@en

P2093

Hicklin DJ

http://www.w3.org/2001/XMLSchema#string

Hofmann F

http://www.w3.org/2001/XMLSchema#string

Lane H

http://www.w3.org/2001/XMLSchema#string

Ludwig DL

http://www.w3.org/2001/XMLSchema#string

Mills GB

http://www.w3.org/2001/XMLSchema#string

O'Reilly KE

http://www.w3.org/2001/XMLSchema#string

Rojo F

http://www.w3.org/2001/XMLSchema#string

Rosen N

http://www.w3.org/2001/XMLSchema#string

She QB

http://www.w3.org/2001/XMLSchema#string

Smith D

http://www.w3.org/2001/XMLSchema#string

P2860

Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1)

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

The TOR pathway: a target for cancer therapy

Cancer. Addiction to oncogenes--the Achilles heal of cancer

P304

1500-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1220620

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-05-2925

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16452206

http://www.w3.org/2001/XMLSchema#string

P932

3193604

http://www.w3.org/2001/XMLSchema#string